There were 354 press releases posted in the last 24 hours and 440,595 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Theriva™ Biologics obtiene la designación de fármaco pediátrico poco frecuente por la FDA estadounidense para el VCN-01 para el tratamiento del retinoblastoma

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image